Last Updated | 30 March 2026

1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit
Site Status
Queensland Children's Hospital (QLD)
John Hunter Children's Hospital (NSW)
Sydney Children's Hospital (NSW)
Monash Health Clayton (VIC)
Royal Children's Hospital (VIC)
Women's and Children's Hospital (SA)
Perth Children's Hospital (WA)
Royal Hobart Hospital (TAS)
Children's Hospital at Westmead (NSW)
Starship Children's Hospital (NZ)
Christchurch Hospital (NZ)
Preparing to Open
Open
Temporarily Closed
Closed
Complete
Adult Sites These sites are not monitored. Status may vary.
Diagnosis Stage Newly Diagnosed, Relapsed/Refractory
National Sponsor Boehringer Ingelheim
Open Date 09/12/2020
Conditions Neoplasms
NUT Carcinoma
Patient Range >18 years
Disease Type , Brain and Spinal (Central Nervous System) Tumours, Digestive System Tumours, Endocrine Tumours, Eye Tumours, Female genital tumours, Genetic tumour syndromes, Germ Cell Tumours, Leukaemia / Lymphoma / Blood Disorders, Head and neck tumours, Neuroblastoma and Ganglioneuroblastoma, Kidney (Renal) Tumours, Skin tumours, Soft Tissue and Bone Tumours (Sarcoma), Chest and Lung (Thoracic) Tumours
Study Type Interventional
International Sponsor N/A

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168